We are fully prepared for Brexit which entails the withdrawal of the UK from the European Union. Based on a thorough risk assessment and the development of a comprehensive management plan, our risk profile is low in the event of a ‘no deal’ scenario. We are confident Brexit will not compromise our ability to continue to deliver seamlessly for our customers and patients. Q2
Solutions has completed a full risk assessment and developed a risk management plan with support from outside consultants, our parent company, IQVIA, and insights gained from meetings with UK government officials. Our risk management plan was further refined and optimized following the ‘near-Brexit experience’ in April 2019.
A Message from Our CEO, Brian O’Dwyer
As a member of the global business community, Q2
Solutions continues to monitor the developments around Brexit. Our teams are fully engaged with government officials, industry associations, and service providers in the clinical trial laboratory solutions space. Based on the information available, we do not foresee any disruption. As negotiations and any potential transition period unfold, we will continue to monitor and prepare as we strive to minimize the potential for any business impact from Brexit. Our top priority and commitment is to flawlessly serve patients and our customers.
For More Information
Please contact your business development representative to learn more about our Brexit Readiness Plan. Additionally, you can contact us at firstname.lastname@example.org